AstraZeneca has sold off another sprawling research outpost in its global reorganization, this time ditching half of its Delaware headquarters to JPMorgan for $44 million, according to local reports.
Horizon Discovery Group, which makes and sells tools for genomics research and personalized medicines, has set out to raise about $41.5 million on the AIM market on the London Stock Exchange.
After 25 years at the helm of one of biotech's best-case scenarios, Regeneron CEO Leonard Schleifer has crossed the $1 billion threshold, according to Forbes, thanks largely to the company's blockbuster eye drug. And, with a stable of promising late-stage treatments waiting in the wings, the Tarrytown, NY, executive's most profitable work may still be ahead of him.
The biotech IPO window is open, and Radius Health is preparing to see if it can make the leap and land on Wall Street with about $86 million in hand.
Researchers have found that CardioDx's genetic test for coronary artery disease could help physicians more accurately identify obstructive CAD in patients--and save insurance companies precious dollars.
Eli Lilly is one step closer to launching its promising new diabetes drug dulaglutide--and one step closer to putting a crimp in Novo Nordisk's big-selling rival, Victoza.
Now that many of the major pharma companies have promised to open up, at least somewhat, on their clinical trial data, Novartis has decided to take the pledge as well. But rather than earn plaudits from longtime critics who have castigated the industry for years of secrecy about their clinical trials, it's only likely to stir a growing backlash among commentators who view these moves as far too limited, spurred primarily by a more ambitious approach from European regulators who want to force open the floodgates.
A new miniaturized wearable device has shown potential in the delivery of drugs to the inner ear that could someday treat hearing loss in a less invasive way than via constant injection.
Once Novartis put out the word that it would start "consultations" about the future of its R&D site in Horsham, U.K., there was never much doubt that the pharma giant would go ahead and close the operation, putting the futures of some 400 staffers and 170 consultants in doubt. On Wednesday the pharma giant confirmed those expectations.
Bethesda, MD's Northwest Biotherapeutics has watched as rivals Dendreon and ImmunoCellular have run into serious roadblocks with personalized cancer vaccines over the past year, but with a major Phase III study underway, the biotech believes it can change the narrative.